![Christopher Baum](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christopher Baum
Direttore/Membro del Consiglio presso Helmholtz-Zentrum für Infektionsforschung GmbH
Profilo
Christopher Baum is currently working as a Principal at Hannover Medical School and as a Member-Supervisory Board at Helmholtz-Zentrum für Infektionsforschung GmbH.
He previously worked as a Member-Supervisory Board at Twincore, Zentrum für Experimentelle und Klinische.
Posizioni attive di Christopher Baum
Società | Posizione | Inizio |
---|---|---|
Helmholtz-Zentrum für Infektionsforschung GmbH
![]() Helmholtz-Zentrum für Infektionsforschung GmbH BiotechnologyHealth Technology Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany. | Direttore/Membro del Consiglio | - |
Hannover Medical School | Corporate Officer/Principal | - |
Precedenti posizioni note di Christopher Baum
Società | Posizione | Fine |
---|---|---|
Twincore, Zentrum für Experimentelle und Klinische
![]() Twincore, Zentrum für Experimentelle und Klinische Miscellaneous Commercial ServicesCommercial Services Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke. | Direttore/Membro del Consiglio | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Helmholtz-Zentrum für Infektionsforschung GmbH
![]() Helmholtz-Zentrum für Infektionsforschung GmbH BiotechnologyHealth Technology Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany. | Health Technology |
Twincore, Zentrum für Experimentelle und Klinische
![]() Twincore, Zentrum für Experimentelle und Klinische Miscellaneous Commercial ServicesCommercial Services Twincore, Zentrum für Experimentelle und Klinische, is a research institute based in Hannover, Germany. Twincore specializes in translational infection research, with a focus on viral infections, respiratory infections, and organ-specific immunity and metabolism research. The German company also conducts pre-clinical and clinical studies on vaccines and antiviral antibodies. Twincore has an international team of over 40 scientists from more than 20 nations, and the private company places a strong emphasis on international collaboration and exchange programs. The company has organized several symposiums and publishes research papers on various topics related to infection research. The company was founded in 2008, and the CEO is Ulrich Kalinke. | Commercial Services |
- Borsa valori
- Insiders
- Christopher Baum